Efficacy of Moringa Olifera Lam leaves capsule on Hyperlipidemia
Phase 2
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Registration Number
- CTRI/2022/01/039155
- Lead Sponsor
- prathima institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
angiographically proven coronary artery disease
fasting total triglycerides between 150 and 499 mg/dl
Exclusion Criteria
serious or dysfunctional angina pectoris (higher than Canadian Cardiovascular Society grade II)
clinically manifest heart failure (higher than New York Heart Association grade II)
severe cardiac arrhythmia
acute liver disease or hepatic dysfunction
compromised renal function (plasma creatinine >150 mol/l)
history of partial ileal bypass surgery
any surgical operation or any systemic inflammatory disease within 3 months before randomization
malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in serum triglyceride levels and High density lipoprotein (HDL) levels over a six-month spanTimepoint: 0,1,3,6 months
- Secondary Outcome Measures
Name Time Method side effects of trial drug during study periodTimepoint: 0,1,2,3,4,5,6,months